Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the stock. D. Boral Capital’s price objective indicates a potential upside of 143.90% from the stock’s current price.

Other analysts have also recently issued reports about the company. BTIG Research raised their target price on Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Friday, November 14th. Lake Street Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Finally, Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Coya Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Stock Up 1.3%

Shares of Coya Therapeutics stock traded up $0.08 on Tuesday, hitting $6.15. The stock had a trading volume of 47,421 shares, compared to its average volume of 106,566. Coya Therapeutics has a one year low of $4.65 and a one year high of $8.29. The stock’s 50-day simple moving average is $6.19 and its two-hundred day simple moving average is $6.05. The stock has a market cap of $128.66 million, a price-to-earnings ratio of -5.55 and a beta of 0.20.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. As a group, equities analysts predict that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COYA. Charles Schwab Investment Management Inc. bought a new stake in shares of Coya Therapeutics during the 1st quarter valued at $65,000. Dauntless Investment Group LLC lifted its position in Coya Therapeutics by 199.5% during the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after acquiring an additional 101,932 shares during the period. Citadel Advisors LLC boosted its stake in Coya Therapeutics by 51.3% during the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after acquiring an additional 22,120 shares in the last quarter. Jane Street Group LLC boosted its stake in Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after acquiring an additional 13,176 shares in the last quarter. Finally, Prosperity Wealth Management Inc. grew its holdings in Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after purchasing an additional 3,350 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.